Sensor-based Congestion ALert for Events in Peritoneal Dialysis (SCALE-PD)
Launched by BODYPORT INC. · Jul 1, 2025
Trial Information
Current as of July 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether a special device called the Bodyport Cardiac Scale can help predict when people with kidney disease who use peritoneal dialysis might experience problems caused by too much fluid in their bodies. Peritoneal dialysis is a treatment for kidney failure that removes waste and extra fluid from the body. The goal is to see if this scale can give early warnings of fluid buildup, which can lead to serious health issues.
To join the study, participants need to be 21 years or older, use automated peritoneal dialysis, be able to stand on the scale without help, and speak either English or Spanish (with some support if needed). People who are planning to switch to a different type of dialysis, have a very limited life expectancy, or certain other health conditions may not be able to join. If you take part, you will use the Bodyport Cardiac Scale regularly, and your health will be monitored through a remote system called Vantive Sharesource. This study is currently recruiting participants, and it aims to help improve care for people living with kidney disease on peritoneal dialysis.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age 21 years or older
- • 2. Able to speak and read English, or able to speak and read Spanish and has a caregiver or family member who speaks English and can provide assistance
- • 3. Able to stand on two bare feet unassisted
- • 4. Receiving automated peritoneal dialysis for the treatment of ESKD
- • 5. Followed on the Vantive Sharesource Remote Patient Management Platform
- Exclusion Criteria:
- • 1. Undergoing or plan to undergo hemodialysis in the next 12 months
- • 2. Have a life expectancy of less than 12 months
- • 3. Are pregnant or plan to become pregnant during the next 12 months
- • 4. Weigh greater than 375 lbs
- • 5. Planned kidney transplant within the next 12 months
- • 6. Have an implanted neurostimulator system
About Bodyport Inc.
Bodyport Inc. is an innovative healthcare technology company dedicated to transforming cardiovascular care through advanced remote monitoring solutions. By leveraging cutting-edge biosensor technology and data analytics, Bodyport empowers patients and healthcare providers to monitor heart health in real-time, facilitating early detection of potential issues and enhancing personalized treatment plans. With a commitment to improving patient outcomes and streamlining healthcare delivery, Bodyport is at the forefront of digital health solutions, driving research and clinical trials that aim to redefine the management of cardiovascular diseases.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported